Skip to main content
Log in

The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension

  • Correspondence
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Aitken, M. Global trends in clinical research. PharmaTimes https://www.pharmatimes.com/magazine/2021/julyaugust_2021/global_trends_in_clinical_research (July 2021).

  2. Wong, C. H. et al. Biostatistics 20, 273–286 (2019).

    Article  Google Scholar 

  3. Dowden, H. & Munro, J. Nat. Rev. Drug Discov. 18, 495–496 (2019).

    Article  CAS  Google Scholar 

  4. Mariani, L. & Marubini, E. J. Clin. Oncol. 18, 429–436 (2000).

    Article  CAS  Google Scholar 

  5. Rogatko, A. et al. J. Clin. Oncol. 25, 4982–4986 (2007).

    Article  Google Scholar 

  6. Chiuzan, C. et al. J. Biopharm. Stat. 27, 477–494 (2017).

    Article  Google Scholar 

  7. Schulz, K. F. et al. Int. J. Surg. 9, 672–677 (2011).

    Article  Google Scholar 

  8. Turner, L. et al. Cochrane Database Syst. Rev. 11, MR000030 (2012).

    PubMed  Google Scholar 

  9. Moher, D. et al. PLoS Med. 7, e1000217 (2010).

    Article  Google Scholar 

  10. Dose-Finding CONSORT Extension Project (ICR); https://www.icr.ac.uk/DFCONSORT (accessed 10 October 2021).

Download references

Acknowledgements

This work is funded by a Medical Research Council and National Institute for Health Research (MRC–NIHR) Methodology Research Programme grant: ‘Early Phase Dose-finding Trials: Development of reporting guidance to improve knowledge transfer’ (grant no. MR/T044934/1). C.J.W. was supported in this work by NHS Lothian via Edinburgh Clinical Trials Unit. S.L. was funded through the National Center for Advancing Translational Sciences, National Institutes of Health (grant no. UL1TR001873). T.J. received funding from UK MRC (MC UU 00002/14). This reporting guideline under development is registered on the Enhancing Quality and Transparency of Health Research (EQUATOR) Network database. All the named authors are part of the Dose-Finding CONSORT Extension Executive Committee.

The authors acknowledge the support of E. Garrett-Mayer, D. Ashby, and J. Isaacs, members of the Independent Expert Panel in contributing their expertise and support to this initiative. The authors also thank the late D. Altman for his enthusiasm, inspiration and significant contribution to the initial conception of this work.

Author information

Authors and Affiliations

Authors

Contributions

C.Y., J.d.B., M.D., J.E., S.H., T.J., A.K., S.L., A.M. and C.J.W. were responsible for conception and funding; A.E. and C.Y. drafted the manuscript; all authors critically revised the manuscript for important intellectual content and approved the final version.

Corresponding author

Correspondence to Christina Yap.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yap, C., Bedding, A., de Bono, J. et al. The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension. Nat Med 28, 6–7 (2022). https://doi.org/10.1038/s41591-021-01594-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01594-1

  • Springer Nature America, Inc.

This article is cited by

Navigation